Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
4.110
+0.140 (3.53%)
May 2, 2025, 4:00 PM EDT - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 41 employees as of December 31, 2024. The number of employees increased by 10 or 32.26% compared to the previous year.
Employees
41
Change (1Y)
10
Growth (1Y)
32.26%
Revenue / Employee
n/a
Profits / Employee
-$1,030,683
Market Cap
106.07M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41 | 10 | 32.26% |
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CTNM News
- 4 days ago - Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development - Business Wire
- 6 weeks ago - Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - Business Wire
- 7 weeks ago - Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum - Business Wire
- 2 months ago - Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones - Business Wire
- 2 months ago - Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791 - Business Wire
- 2 months ago - Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference - Business Wire
- 4 months ago - Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
- 4 months ago - Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire